(NewsDirect)
ORLANDO, FL /September 20, 2023 ( PlatoData via 500NewsWire) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), aleading developer of transdermal pharmaceutical products, proudlyannounces the issuance of a U.S. patent for its cutting-edge AVERSA™Technology. This groundbreaking innovation, utilizing taste aversion,marks a paradigm shift in addressing the primary routes of abuseassociated with opioid-based transdermal patches.
The newly grantedpatent, numbered U.S. patent 11,759,431, titled "Abuse and MisuseDeterrent Transdermal Systems," significantly bolstersNutriband's intellectual property protection in the United States.It covers a range of abuse deterrent transdermal products, all rootedin the proprietary AVERSA™ abuse deterrent technology. Thispioneering technology seamlessly integrates into transdermal patches,effectively countering abuse, diversion, misuse, and accidentalexposure of drugs with abuse potential.
Nutriband's flagship product in development, AVERSA™Fentanyl, leads the charge in revolutionizing pain management. It aimsto become the market's premier abuse deterrent pain patch, settingnew standards for safety. This patent signifies a pivotal milestone inNutriband's strategic vision to fortify its intellectual propertyfoundation around its proprietary abuse deterrent technology. With aglobal reach encompassing 45 countries, Nutriband's IP portfoliosolidifies its position in the market. AVERSA™ Fentanyl, thecompany's flagship product, recently projected peak annual U.S.sales ranging from $80M to $200M.
Nutriband's AVERSA™ abuse deterrent transdermaltechnology presents a transformative solution to enhance the safetyprofile of transdermal drugs susceptible to abuse. AVERSA™ not onlyensures continued access for patients in need but also minimizes therisk of abuse, diversion, misuse, and accidental exposure. Backingthis pioneering technology is a robust intellectual propertyportfolio, with patents granted in various countries, including theUnited States, Europe, Japan, Korea, Russia, Canada, Mexico, andAustralia.
About NutribandInc.
NutribandInc. is a leader in developing transdermal pharmaceutical products. Atthe forefront is the company's flagship product, an abusedeterrent fentanyl patch incorporating the groundbreaking AVERSA™abuse-deterrent technology. AVERSA™ technology can be seamlesslyintegrated into any transdermal patch to counteract abuse, misuse,diversion, and accidental exposure of drugs with abusepotential.
Formore information, visit www.nutriband.com .
Forward-LookingStatements
This press release contains forward-looking statements thatinvolve known and unknown risks and uncertainties. The Company'sactual results may differ materially from those anticipated in itsforward-looking statements. Factors that may cause such differencesinclude the Company's ability to develop its proposed abusedeterrent fentanyl transdermal system, obtain patent protection forits abuse technology, secure necessary financing, obtain regulatoryapprovals, and market its products effectively. The Company undertakesno obligation to revise or update any forward-looking statements toreflect events or circumstances that may arise after the datehereof.
This Press Release is created by PlatoAi
Contact Details
David Zazoff - MDMWorldwide
Copyright (c) 2023 TheNewswire - All rights reserved.